Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Long-Term Deferred Tax (2018 - 2019)

Akebia Therapeutics (AKBA) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $109.4 million as the latest value for Q4 2019.

  • Quarterly Long-Term Deferred Tax fell 3.04% to $109.4 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $109.4 million through Dec 2019, down 3.04% year-over-year, with the annual reading at $109.4 million for FY2019, 3.04% down from the prior year.
  • Long-Term Deferred Tax for Q4 2019 was $109.4 million at Akebia Therapeutics, down from $112.8 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $112.8 million in Q4 2018, with the low at $109.4 million in Q4 2019.